Panbela Therapeutics, Inc. Common Stock (PBLA)

PBLA was delisted on the 6th of March, 2024.

• Market cap: $3.86M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Employees: 7